Top ▲

immunoglobulin heavy constant epsilon

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 2741

Nomenclature: immunoglobulin heavy constant epsilon

Family: Immunoglobulins

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 428 14q32.33 IGHE immunoglobulin heavy constant epsilon
Mouse - - 12 F1 Igh-7 immunoglobulin heavy chain 7 (heavy chain of IgE)
Previous and Unofficial Names Click here for help
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  M1' peptide from IgE bound by humanized antibody 47H4 Fab
PDB Id:  3HR5
Ligand:  quilizumab
Resolution:  2.4Å
Species:  Mouse
References:  2

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
ligelizumab Peptide Primary target of this compound Immunopharmacology Ligand Hs Binding 9.9 – 11.8 pKd 1,4
pKd 9.9 – 11.8 (Kd 1.39x10-10 – 1.47x10-12 M) [1,4]
Description: In vitro binding affinity
quilizumab Peptide Primary target of this compound Immunopharmacology Ligand Hs Binding 8.8 pKd 5
pKd 8.8 (Kd 1.5x10-9 M) [5]
omalizumab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding 7.6 – 8.2 pKd 1,3
pKd 8.2 (Kd 6.98x10-9 M) [1]
Description: In vitro binding affinity
pKd 7.6 (Kd 2.6x10-8 M) [3]
Description: F(ab) apparent binding affinity of e25 measured by surface plasmon resonance
Immunopharmacology Comments
IgE is being investigated as a molecular target in allergic inflammatory conditions such as asthma, allergic rhinitis and chronic spontaneous urticaria. One anti-IgE monoclonal, omalizumab, has already been approved for use in patients with asthma or chronic spontaneous urticaria. Omalizumab binds to circulating free IgE. The hunt for additional IgE-targeting antibodies is ongoing. Quilizumab, is one such investigational agent that targets the membrane bound IgE (mIgE) which forms the allergen-binding component of the B cell receptor.
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Antigen presentation
Immuno Process:  T cell (activation)
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Cytokine production & signalling
Immuno Process:  Cellular signalling


Show »

1. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014) Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy, 44 (11): 1371-85. [PMID:25200415]

2. Brightbill HD, Jeet S, Lin Z, Yan D, Zhou M, Tan M, Nguyen A, Yeh S, Delarosa D, Leong SR et al.. (2010) Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest, 120 (6): 2218-29. [PMID:20458139]

3. Lowman HB, Presta LG, Jardieu PM, Lowe J. (1999) Anti-IgE antibodies and methods of improving polypeptides. Patent number: US5994511. Assignee: Genentech, Inc.. Priority date: 02/07/1997. Publication date: 30/11/1999.

4. Singh S, Foster C, Wu H. (2009) High affinity anti-human IgE antibodies. Patent number: US7531169 B2. Assignee: Tanox, Inc.. Priority date: 01/02/2003. Publication date: 12/05/2009.

5. Wu L, Balazs M, Brightbill H, Chan A, Chen Y, Chuntharapai A, Dennis M, Wong T. (2011) Apoptotic anti-IgE antibodies. Patent number: US8071097 B2. Assignee: Genentech, Inc.. Priority date: 22/03/2007. Publication date: 06/12/2011.

How to cite this page

Immunoglobulins: immunoglobulin heavy constant epsilon. Last modified on 08/05/2017. Accessed on 20/07/2024. IUPHAR/BPS Guide to PHARMACOLOGY,